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Abstract
Aim Cholangitis is the most common infectious complication
of ERCP. In vitro studies showed that addition of aminoglyco-
sides to contrast mediumwas effective in reducing cholangitis
but the results of clinical trials are conflicting. We studied the
effect of adding gentamicin to contrast medium in reducing
the rate of post-ERCP cholangitis in patients with non-
calculous obstructive jaundice.
Methods All patients with non-calculous obstructive jaun-
dice who underwent endoscopic biliary stenting at the Shar-
iati Hospital, Tehran, between December 2009 and October
2010 were enrolled in the study. Gentamicin (10 mg) or
distilled water was added to each 10 cc contrast medium
during ERCP. Intravenous antibiotics were administered
before and after the procedure in all patients. After ERCP
and stent deployment, patients were followed for 72 h for
symptoms and signs of cholangitis.
Results A total of 114 patients were eligible for the study. Of
these, 57 patients were included in each group. Cholangiocar-
cinomawas the most prevalent diagnosis. The obstruction was
relieved in all patients by stenting. Five patients in each group
(8.8 %) developed cholangitis. There was no significant dif-
ference in the incidence of cholangitis between the two groups
(p01.000).
Conclusions With adequate drainage of the obstructed bili-
ary tract by proper stenting, adding gentamicin to contrast
media had no significant effect on incidence of post-ERCP
cholangitis.
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Introduction
Endoscopic retrograde cholangiopancreatography (ERCP) is a
standard therapeutic modality in pancreatobiliary disorders.
However, it is associated with some complications including
pancreatitis, bleeding, perforation, and sepsis. Cholangitis is the
most common infectious complication of ERCP [1]. Risk
factors of post-ERCP cholangitis are failure to obtain adequate
biliary drainage, Klatskin’s tumor (range: 14 % to 53 %),
primary sclerosing cholangitis (PSC), occlusion in biliary
stents, jaundice, low annual case volumes, and both percuta-
neous and endoscopic procedures [2–9]. A few suggestions
have been made to prevent post-ERCP cholangitis, including
thorough disinfection of endoscope and accessories, use of low
volume of contrast solutions, decompression of obstruction,
prophylactic use of antibiotics, and percutaneous or surgical
decompression in cases of ERCP failure [10]. In vitro studies
have found that adding antibiotics to the contrast agent was
useful, but only a few clinical studies have evaluated its use in
ERCP with conflicting results [11–16]. Collen et al. [13] exam-
ined the efficacy of adding gentamicin to contrast agent and
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concluded that it did not reduce infectious complications. How-
ever, this study was done in simple pancreatobiliary disorders
and many years before today’s therapeutic ERCP. Recently, a
retrospective study [14] on 6,695 ERCP in 2005 concluded that
adding antibiotics to the contrast agent and intravenous anti-
biotics can reduce infectious complications of ERCP. In the
present double-blind randomized controlled trial, we evaluated
the effect of adding gentamicin to contrast media for preventing
post-ERCP cholangitis, in non-calculous biliary obstruction.
Methods
Between December 2009 and October 2010, all patients
with non-calculous biliary obstructions, e.g. cholangiocarci-
noma, pancreatic cancer, sclerosing cholangitis, postsurgical
benign biliary strictures, and biliary stenosis due to meta-
static cancers to biliary tree who were candidates for pallia-
tive stenting, were included in this study. Patients with
biliary stones, those who were candidates for surgical treat-
ment, those who were already febrile, and those not con-
senting to the study protocol were excluded (Fig. 1).
Cholangitis was defined as the presentation of fever with or
without chills within the first 72 h after ERCP. The primary
pancreatobiliary disorder was documented by radiology,
ERCP findings, endoscopic ultrasound, or surgery. Patients
were randomized to receive either 10 mg (2 mL) gentamicin
(intervention group) or distilled water (placebo group) in
10 mL contrast medium (Meglumine; Bracco Diagnostics
Inc., China). Gentamicin or placebo (distilled water) was
added just before the scheduled stenting based on the random
table prepared by a physician who was not involved in the
ERCP procedure and was not aware of the clinical status of the
patient. Distilled water was added as placebo and the volume
was similar to that of gentamicin. The dose of gentamicin was
based on previous studies [11–13].
Randomization was done by a computer-generated ran-
domization table. Based on an expected incidence of chol-
angitis of 25 % Rerknimitr et al. [4] in the placebo group
and to detect a 20 % reduction in the incidence of cholangi-
tis in the treatment group, we calculated a sample size of 57
patients in each group to give 80 % power to detect a
significant difference between gentamicin and placebo. All
the study personnel and participants were blinded to treat-
ment assignment for the duration of the study. Only the
study statisticians and data monitoring committee had
access to allocation data, and these individuals did not have
contact with the study participants. The study was approved
by the institutional review board of the Digestive Diseases
Research Center of Tehran University of Medical Sciences.
Written informed consent was obtained according to the
guidelines of the institute.
All patients were administered 2 g ceftriaxone intravenously
30 min before ERCP and daily for 3 days. After ERCP, patients
were admitted for 72 h. Blood culture was performed if they
developed fever (oral temperature >37.2 °F). Any fever, chills,
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or positive blood culture was recorded. The study end point
was developing cholangitis within 72 h after the procedure.
Data on patients’ demographics, ERCP findings, and com-
plications were analyzed with SPSS version 16 (SPSS Inc.,
Chicago, IL, USA) using chi-square or Fischer’s exact test.
Results
A total of 114 patients were eligible for inclusion in the study;
57 patients were allocated to each group. The mean age of
patients in the intervention and placebo groups was 66.4 and
62.8 years, respectively, and most patients were male. Chol-
angiocarcinoma was the most prevalent diagnosis in both
groups, and jaundice was the most frequent symptom. Dem-
ographics of subjects are presented in Table 1. There was no
significant difference at baseline between the study groups.
Details of ERCP data are given in Tables 2 and 3. Median
number of cannulation attempts was 2, and volume of contrast
injection was 10 mL in both groups (p00.70 and 0.14, respec-
tively). For most patients, only a single stent was deployed (56
in placebo group, 57 in intervention group). Metallic stent was
deployed for 22 (38.6 %) patients in the placebo group and 15
(26.3 %) in the interventional group (p0NS).
Ten patients (5 in each group; 6 males) developed post-
ERCP cholangitis. Five of these patients with cholangitis had
received less than 10 mL contrast media. Five patients with
metallic stents and five with plastic ones developed cholangi-
tis. No patient with two stents deployment developed chol-
angitis, and six patients with cholangitis had stent deployment
in the common bile duct (CBD). Only location of stent
deployment in CBD had significant correlation with incidence
of post-ERCP cholangitis. After multivariable regression anal-
ysis for location of stent deployment, cannulation attempts,
and volume of contrast injection, the site of stent still had
significant statistical correlation with developing post-ERCP
cholangitis (p00.02, 95 % CI00.038–0.768; Table 2).
One patient in intervention group with diagnosis of PSC
died because of septic shock. In addition, one patient each
died of myocardial infarction and severe pancreatitis (both in
placebo group). Three patients developed mild pancreatitis
and one had post-ERCP cholecystitis.
Discussion
The authors found that adding gentamicin to contrast media
did not alter the incidence of post-ERCP cholangitis. Adding
aminglycosides to contrast media was first introduced by
Jendrzejewski et al. [11] in 1980. They found that in vitro
Table 2 ERCP characteristics
in the study groups Patients demographics Placebo group Intervention group p-value
Median number of cannulation attempt 2 (range: 1–10) 2 (range: 1–20) 0.70
34/23 36/21
Median volume of contrast 10 (range: 2–60) 10 (range: 2–35) 0.14
38/19 45/12
Metallic/plastic stent (%) 22/35 15/42 0.16
(38.6/61.4) (26.3/73.7)
One/two stents (%) 56/1 55/2 1.000
(98.2/1.8) (96.5/3.5)
CBD/other stenting site (%) 50/7 50/7 1.000
(87.7/12.3) (87.7/12.3)










Male gender 36 (63.2) 42 (73.7) 0.23
Mean age (SD) 66.42 (14.20) 62.82 (14.76) 0.18
Clinical diagnosis 0.86
Cholangiocarcinoma 17 (29.8) 18 (31.6)
Pancreas tumor 17 (29.8) 16 (28.1)
Ampullary tumor 11 (19.3) 11 (19.3)
Others 12 (21.1) 12 (21.0)
Nausea 23 (40.4) 16 (28.1) 0.16
Abdominal pain 36 (63.2) 37 (64.9) 0.84
Weight loss 42 (73.7) 39 (68.4) 0.53
Jaundice 52 (91.2) 54 (94.7) 0.71
Pruritus 42 (73.7) 41 (71.9) 0.83







Male/female 2/3 4/1 0.72
Median cannulation attempt 3/2 1/4 0.13
Median volume of contrast 2/3 3/2 0.14
Metallic/plastic stent 4/1 1/4 0.29
One/two stents 5/0 5/0 1.000
CBD/other stenting sites 2/3 4/1 0.02
Indian J Gastroenterol
addition of aminoglycosides to iodinated contrast agents and
bile did not interfere with their antibactericidal activity and
could prevent growth of organisms producing cholangitis.
Ramirez et al. [12] studied the effect of adding gentamicin to
contrast medium in artificial bile ducts resembling biliary
ducts and added gentamicin-sensitive and -resistant pseudo-
monas to this medium. They found that contrast medium was
bacteriostatic in itself and addition of gentamicin to it could
eliminate sensitive bacteria and reduce the resistant-form col-
onies. This study supported the idea of theoretical benefit of
intracontrast aminoglycosides, especially in resistant bacteria,
which are prevalent in ERCP.
In 1980, Collen et al. [13] studied the addition of genta-
micin to contrast media in a randomized controlled trial.
They added gentamicin or placebo to Renograffin-60 for
prevention of post-ERCP cholangitis. They did not use
intravenous antibiotics before ERCP. They concluded that
adding gentamicin had no significant effect on reducing the
incidence of post-ERCP cholangitis, but this study was long
before new era of therapeutic ERCP and also contained
patients with low risk of post-ERCP cholangitis. The sample
size in this study was also small.
In 2005, Bernadino et al. [14] reported their 14 years
study of 6,695 ERCP in an abstract. In their study, patients
were divided into high-risk (hilar obstruction, sclerosing
cholangitis, pancreatic strictures and stones, or pseudocysts)
and low-risk (noninfected cases) groups. All patients in
high-risk group received intravenous and intracontrast anti-
biotics and low-risk patients did not. They concluded that
with this selective adoption, infectious complications of
ERCP could be reduced to near zero. Their study had a
large sample size and long follow up for up to one month,
but it was not randomized and all high-risk patients received
both intravenous and intracontrast antibiotics, which made
assessment of the role of intracontrast antibiotics difficult.
In the present study, the addition of gentamicin to con-
trast medium had no significant effect in reduction of post-
ERCP cholangitis. Furthermore, the incidence of cholangitis
had no association with gender, number of cannulation
attempts, volume of contrast injected, or type and number
of deployed stents. Only the location of stent deployment
correlated with development of cholangitis, and patients
with stents placed in CBD were more likely to develop
cholangitis. There is no explanation for this finding.
To the best of our knowledge, this study is the first double-
blind randomized controlled trial that studied intracontrast
aminoglycosides for prevention of biliary stenting infectious
complications. In this study, high-risk patients for post-ERCP
cholangitis were included, and effect of prophylactic intra-
venous antibiotics was eliminated by administering them to all
patients. Numbers of different diagnoses were almost similar
in the two groups, again potentiating the results. The main
limitation of this study is the small sample size.
In conclusion, in cases with adequate biliary drainage after
ERCP, adding gentamicin to contrast media had no significant
effect in reduction of incidence of post-ERCP cholangitis.
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